Omnimmune Holdings (OTCPK:OMMH) - Stock Price, News & Analysis

OMMH Stock Overview

OMMH fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($980)

Shares are highly illiquid

Latest financial reports are more than a year old

Omnimmune Holdings, Inc. Competitors

eFFECTOR Therapeutics

OTCPK:EFTR

US$940.0

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

ObsEva

OTCPK:OBSE.F

US$11.7k

Vaxxinity

OTCPK:VAXX

US$12.7k

Price History & Performance

Summary of all time highs, changes and price drops for Omnimmune Holdings
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0001
52 Week Low	US$0.000067
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-99.44%
5 Year Change	-98.04%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	OMMH	US Biotechs	US Market
7D	0%	4.3%	1.6%
1Y	n/a	18.8%	32.3%

Return vs Industry: Insufficient data to determine how OMMH performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how OMMH performed against the US Market.

Price Volatility

Is OMMH's price volatile compared to industry and market?
OMMH volatility
OMMH Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: OMMH has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine OMMH's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	n/a	n/a

Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States. The company owns rights for monoclonal antibody technologies. It also intends to develop personalized cancer treatment with the selection of prophylactic and therapeutic vaccines (active immunization), monoclonal antibodies (passive immunization), and genomic-based products, which target a hormone called human chorionic gonadotropin.

Omnimmune Holdings, Inc. Fundamentals Summary

How do Omnimmune Holdings's earnings and revenue compare to its market cap?
OMMH fundamental statistics
Market cap	US$980.00
Earnings (TTM)	-US$1.79m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is OMMH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OMMH income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$1.79m
Earnings	-US$1.79m

Last Reported Earnings

Sep 30, 2010

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did OMMH perform over the long term?

See historical performance and comparison